Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
NCT04788043Phase 2Terminated
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of magrolimab in classic Hodgkin lymphoma (cHL). Started Jun 2022; status: terminated.
02
Drugs
magrolimab
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04788043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04788043.